Clinical Trials Logo

BRAF Gene Mutation clinical trials

View clinical trials related to BRAF Gene Mutation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03784378 Completed - Ovarian Cancer Clinical Trials

Continued Access to RXDX-105

Start date: December 14, 2018
Phase: Phase 1
Study type: Interventional

This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.

NCT ID: NCT03750175 Completed - Clinical trials for Colorectal Cancer Metastatic

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

OPTIPAL-II
Start date: June 1, 2018
Phase:
Study type: Observational

The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

NCT ID: NCT02367859 Completed - BRAF Gene Mutation Clinical Trials

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Start date: July 17, 2017
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01700582 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Start date: April 2012
Phase:
Study type: Observational

The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer patients to targeted therapies (commercially available or through clinical trials). The objective of the BIOMARKERS-France study is to describe the epidemiological, clinical and molecular characteristics of these patients and their tumors and to assess the impact of these analyzes on their treatment (ie bio-guided therapy) as well as outcomes (response rate, progression free and overall survival).

NCT ID: NCT01531361 Completed - Clinical trials for Advanced Malignant Neoplasm

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Start date: February 6, 2012
Phase: Phase 1
Study type: Interventional

This phase I clinical trial studies vemurafenib with sorafenib tosylate or crizotinib in treating patients with advanced malignancies with BRAF mutations. Sorafenib tosylate and crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of advanced malignancies by blocking blood flow to tumors. Drugs used in chemotherapy, such as vemurafenib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vemurafenib together with sorafenib tosylate or crizotinib may kill more cancer cells.